![Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epide... | OncologyPRO Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epide... | OncologyPRO](https://i.ytimg.com/vi/hqPUk_QzYJQ/maxresdefault.jpg)
Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epide... | OncologyPRO
![Novartis Presents Updated Data on Efficacy, Safety of Kisqali plus Letrozole | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology Novartis Presents Updated Data on Efficacy, Safety of Kisqali plus Letrozole | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology](https://media.americanpharmaceuticalreview.com/m/28/article/338385.jpg)
Novartis Presents Updated Data on Efficacy, Safety of Kisqali plus Letrozole | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
![Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III ( MONALEESA-3) Trial for the Treatment of HR+/HER2- Advanced Breast Cancer Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III ( MONALEESA-3) Trial for the Treatment of HR+/HER2- Advanced Breast Cancer](https://www.pharmashots.com/public/images/20220315161712_original_43.webp)
Novartis Updated Exploratory OS Analysis of Kisqali (ribociclib) in P-III ( MONALEESA-3) Trial for the Treatment of HR+/HER2- Advanced Breast Cancer
![Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0960977620301867-gr2a.jpg)
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients | Novartis
![Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4f9658d8-48ac-42eb-ac8f-23e584abd35c/gr2.jpg)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial - The Lancet Oncology
Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
![MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram](https://www.researchgate.net/publication/328390587/figure/fig1/AS:683497253515267@1539969852276/MONALEESA-2-subgroup-analysis-of-locally-assessed-PFS-Data-cut-off-2-January-2017.png)
MONALEESA-2 subgroup analysis of locally assessed PFS. Data cut-off, 2... | Download Scientific Diagram
![Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/97e331df-3067-446e-b347-644f7056f58b/gr2c_lrg.jpg)
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - The Breast
![Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13058-018-1050-7/MediaObjects/13058_2018_1050_Fig1_HTML.png)
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
![Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials | Oncology Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials | Oncology](https://www.frontiersin.org/files/Articles/455698/fonc-09-00510-HTML/image_m/fonc-09-00510-g001.jpg)
Frontiers | Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials | Oncology
![Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial - Clinical Breast Cancer Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial - Clinical Breast Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/6a66d6d1-dd9d-4ee6-9c02-ec1cc0a1a7c0/gr1.jpg)
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2− Advanced Breast Cancer in the MONALEESA-3 Trial - Clinical Breast Cancer
Download Poster: Overall Survival with Kisqali® plus Endocrine Therapy in Patients with Advanced Breast Cancer with Visceral Metastases 6
![Breast Cancer - ASCO 2021 Breast/Gyn - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options Breast Cancer - ASCO 2021 Breast/Gyn - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/2021/clinical-oncology-2021/breast-and-gyn/onc_2021_cf_asco-breast_gyn_ea_thumbnails/onc_2021_cf_asco-breast_gyn_ea_thumb-19.png?rev=eacfe83628b34e6083009a6beadedbab)
Breast Cancer - ASCO 2021 Breast/Gyn - Breast Cancer and Gynecologic Cancers - 2021 ASCO Virtual Annual Meeting - Oncology - Clinical Care Options
![Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41416-021-01415-9/MediaObjects/41416_2021_1415_Fig1_HTML.png)
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d7f73f34-7510-4416-a52b-e41693a5eaed/gr4_lrg.jpg)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
![Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/44899b13-721b-49c0-acd7-ab9c0276b0ac/gr1_lrg.jpg)